Table 1.
Basic characteristics of the study cohort: T = temporal, F = frontal, P = parietal, O = occipital, F–P = frontoparietal, 3D-CRT = Three-Dimensional Conformal Radiotherapy, IMRT = Intensity-Modulated Radiotherapy.
| Basic characteristics |
Study cohort n = 39 |
Validation n = 16 |
p |
|---|---|---|---|
| Age at initial diagnosis (years) | |||
| Median | 51 | 54 | 0.7 |
| Range | 29–66 | 35–64 | |
| Sex (n) | |||
| Men | 28 (72%) | 10 (63%) | 0.5 |
| GBM location (%) | |||
| T/F/P/O/F-P | 38/29/19/5/9 | 34/31/14/7/14 | 0.7 |
| Radiotherapy | |||
| Median dose (Gy) | 60 | 60 | 0.9 |
| Technique 3D-CRT/IMRT (%) | 30/70 | 40/60 | 0.8 |
| Cycles of adjuvant TMZ | |||
| Median | 6 | 6 | 0.9 |
| Range | 1–12 | 4–10 | |
| Time to graphic progression (months) | |||
| Median (95% CI) | 6.7 (2.9–9.6) | 6.1 (4.8–8.8) | 0.8 |
| Diagnosis validation | |||
| Biopsy/subsequent imaging (%) | 67/33 | 75/25 | 0.6 |
| Final diagnosis | |||
| Tumor recurrence | 29 (75%) | 12 (75%) | 1 |
| Pseudoprogression | 10 (25%) | 4 (25%) | |
| Overall survival (months) | |||
| Median (95% CI) | 14.5 (12.9–17.4) | 14.0 (13.1–15.2) | 0.8 |